Vivani Medical to Merge Subsidiary Cortigent with ClearOne, Creating New Public Entity

summarizeSummary

Vivani Medical is merging its subsidiary, Cortigent, with ClearOne, Inc. to create a new public company, securing significant financing and retaining control of the combined entity.

check_boxKey Events · M&A and Partnerships · VANI

• Merger Agreement Signed

  Vivani Medical's wholly-owned subsidiary, Cortigent, Inc., will merge with ClearOne, Inc., a Nasdaq-listed company, becoming a wholly-owned subsidiary of ClearOne.

• Merger Consideration & Control

  Vivani will receive 12,500,000 shares of ClearOne common stock. Vivani will designate 4 of the 5 board members for the combined company, including the Chairperson, and its designee will serve as CEO.

• New Financing for Combined Entity

  ClearOne will raise a minimum of $10,000,000 and a maximum of $15,000,000 through an S-1 registration, issuing 2,500,000 to 5,000,000 units, each consisting of one share of common stock and one warrant exercisable at $10.00 per share for six months.

• Equity Lock-up and Moratorium

  Vivani's consideration shares are subject to a 1-year (50%) and 2-year (50%) lock-up. The combined company will also have a 12-month equity issuance moratorium, with certain exceptions.

auto_awesomeAnalysis · VANI · Industrial Applications And Services

This 8-K announces a definitive merger agreement where Vivani Medical's wholly-owned subsidiary, Cortigent, Inc., will merge with ClearOne, Inc., a Nasdaq-listed company. Vivani will receive 12.5 million shares of ClearOne common stock, and ClearOne will raise $10M-$15M in new financing. This transaction effectively creates a new publicly traded entity focused on Cortigent's business, with Vivani retaining significant ownership and control (designating 4 of 5 board members, including the CEO). This is a major strategic move to advance Cortigent's drug development programs and secure substantial capital.